16:36:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-04-18 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-04-19 Ordinarie utdelning LYTIX 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-22 Ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar nya cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo, Norge.
2023-07-20 08:00:00
Oslo, 20 July 2023. Lytix Biopharma - Lytix Biopharma AS ("Lytix") (Euronext
Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today announces
that an abstract with clinical data from the ATLAS-IT-05 study is accepted for
presentation at ESMO 2023.

In ATLAS-IT-05, a Phase II study, LTX-315 is given to patients with advanced
melanoma in combination with the immune checkpoint inhibitor pembrolizumab
(Keytruda), a market leading approved immunotherapeutic antibody. In the
abstract, interim efficacy and safety data from the first patients enrolled in
the Phase II study are presented.

The interim data will be presented by the leading investigator of the trial,
Professor Stéphane Dalle (Centre Hospitalier Universitaire de Lyon, France) in a
poster session. The poster title is: Intratumoral injection of LTX-315 in
combination with pembrolizumab in patients with advanced melanoma refractory to
prior PD-1/PD-L1 therapy: interim results from the ATLAS-IT-05 trial.


Øystein Rekdal, CEO of Lytix commented: "We are looking forward to sharing
interim data from the ongoing ATLAS-IT-05 trial at this year's ESMO in Madrid.
The study is running at several sites in the US and Europe exploring the ability
of LTX-315 to alter the course of disease in patients who have previously failed
treatment with anti-PD-1/PDL-1."
For more information about ATLAS-IT-05:
https://clinicaltrials.gov/study/NCT04796194
For more information about the conference:
https://www.esmo.org/meeting-calendar/esmo-congress-2023


***

For more information, please contact:
Ole Peter Nordby, Head of IR & Communication Manager:
ole.peter.nordby@lytixbiopharma.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class molecule representing a new and
superior in situ therapeutic principle to boost anti-cancer immunity, with the
potential to be the ideal combination partner with other types of
immunotherapies. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.